Document is current
Any future updates will be listed below
-
Authors
Jung, Hyunchul https://orcid.org/0000-0003-0450-2190
Yang, Tsun-Po
Walker, Susan https://orcid.org/0000-0002-5016-6426
Danecek, Petr
Garcia-Salinas, O. Isaac https://orcid.org/0000-0003-2550-569X
Neville, Matthew D. C. https://orcid.org/0000-0001-5816-7936
Christopher, Joseph
Cortés-Ciriano, Isidro https://orcid.org/0000-0002-2036-494X
Firth, Helen
Scally, Aylwyn https://orcid.org/0000-0002-0807-1167
Hurles, Matthew https://orcid.org/0000-0002-2333-7015
Campbell, Peter https://orcid.org/0000-0002-3921-0510
Rahbari, Raheleh https://orcid.org/0000-0002-1839-7785
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/W025353/1)
Cancer Research UK (Cancer Research UK)
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 25 September 2025
First Online: 3 November 2025
Competing interests
: P.J.C. is a co-founder, shareholder, and consultant for Quotient Therapeutics, M.E.H. is a co-founder of, consultant to and holds shares in Congenica, a genetics diagnostic company. All remaining authors declare no competing interests.
